Cipla wins approval for generic testosterone in the US

Drug maker Cipla said it received final approval for selling a generic testosterone injection in the US.

Cipla’s Testosterone Cypionate Injection 100mg /ml and 200mg /ml is an AO-rated generic equivalent version of Pharmacia and Upjohn’s Depo-Testosterone.

Depo-Testosterone and its generic equivalents h ad US sales of approximately $191 M, according to IQVIA.

The drug is used for replacement therapy in males in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

Cipla said the product is available for shipping immediately.

The company sells pharmaceutical products in over 80 countries and has over 1500 products in its portfolio.